Content Type: Commentary & Opinion

A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs

March 16, 2026

Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act

March 16, 2026

Insulin Access and Affordability in the USA: Anticipating the First Interchangeable Insulin Product

March 16, 2026

Implementing U.S. COVID-19 Testing: Regulatory and Infrastructural Challenges

March 16, 2026

Drug Evaluation During the COVID-19 Pandemic

March 16, 2026

Pharmaceutical Marketing and the New Social Media

March 16, 2026

The Safety of Prescription Drugs

March 16, 2026

Patient Assistance Programs and the Anti-Kickback Statute: Charting a Pathway Forward

March 16, 2026

Continual Learning in Medical Devices: FDA’s Action Plan and Beyond

March 16, 2026

Safeguarding Evidence-Based Decision Making in the FDA for COVID-19 Vaccines

March 16, 2026

Value-Based Pricing of Drugs with Multiple Indications or in Combinations—Lessons From Europe

March 16, 2026

Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability

March 16, 2026